Cell-surface receptors guide antisense therapy to mutant KRAS in pancreatic cancer cells
Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer. In a study published in the Journal of Cell Biology (JCB), researchers at the Cancer Research UK Scotland Institute and the University of Glasgow identify a pathway by which ASOs enter cells and reach their targets,…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
